News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Albuminuria reduction fuels finerenone’s kidney benefits
- Author:
- Mitchel L. Zoler, PhD
Mediation analyses of finerenone trial data show most of the drug’s kidney benefit and a third of its CVD benefit comes from cutting albuminuria...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/165913_Inker_Leslie_MA_web.jpg)
CKD-EPI eGFR formula surpasses alternatives in young adults
- Author:
- Mitchel L. Zoler, PhD
The 2021 race-free CKD-EPI equation for estimating glomerular filtration rate outperformed two alternative formulas in adults aged 18-40 years.
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Risk calculator for early-stage CKD may soon enter U.S. market
- Author:
- Mitchel L. Zoler, PhD
Klinrisk, which estimates an adult’s risk for CKD progression from 20 lab values, may spur more targeted, intensified treatment.
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Aprocitentan reduces resistant hypertension in CKD
- Author:
- Mitchel L. Zoler, PhD
Aprocitentan, a novel dual endothelin antagonist, showed antihypertensive efficacy and manageable safety in people with chronic kidney disease.
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
EMR prompt boosts albuminuria measurement in T2D
- Author:
- Mitchel L. Zoler, PhD
An EMR prompt in primary care to measure albuminuria and eGFR in adults with type 2 diabetes boosted screening by about 50%.
News
Higher weight loss on tirzepatide links to seven factors
- Author:
- Mitchel L. Zoler, PhD
“These findings may provide valuable information to clinicians and people with type 2 diabetes regarding the likelihood of achieving substantial...
News
FDA gives semaglutide two drug safety–related label changes
- Author:
- Mitchel L. Zoler, PhD
The second addition concerns a new adverse reaction that was identified during the postmarketing experience: gastrointestinal ileus, an intestinal...
News
Echocardiography boosts prognostic power in T1D
- Author:
- Mitchel L. Zoler, PhD
“MPI has been around for many years, but our technique is rather novel” and has high intra- and inter-observer reproducibility. “It’s highly...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA panel rejects implanted GLP1-RA dosing device for T2D
- Author:
- Mitchel L. Zoler, PhD
“The data show concerning safety signals that need further investigation.”
News
SGLT2i safety in acute heart failure confirmed by new data
- Author:
- Mitchel L. Zoler, PhD
Dapagliflozin appeared to improve diuresis and natriuresis while reducing the administered diuretic dose.
News
Screening finds high rates of CVD in diabetes, COPD patients
- Author:
- Mitchel L. Zoler, PhD
The study tested a “very simple” symptom questionnaire as the initial screening phase, yet resulted in a CVD diagnostic rate that was two- to...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
More weight loss linked with more benefit in STEP-HFpEF
- Author:
- Mitchel L. Zoler, PhD
“The outcomes we’ve already seen in STEP-HFpEF were largely symptomatic, which are extraordinarily important, but there may be a completely...
News
ESC backs SGLT2 inhibitor plus GLP-1 in diabetes with high CVD risk
- Author:
- Mitchel L. Zoler, PhD
Another major change in the new ESC guideline revision is introduction of a CVD risk calculator intended to estimate the risk among people with...
News
Liraglutide fixes learning limit tied to insulin resistance
- Author:
- Mitchel L. Zoler, PhD
The normalization in associative learning that one dose of liraglutide produced in people with obesity “fits with studies showing that these drugs...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Wegovy scores HFpEF benefits in people with obesity
- Author:
- Mitchel L. Zoler, PhD
The results “indicate that treatment with semaglutide is a valuable therapeutic approach in the management of patients with HFpEF and obesity.”